Clinical trials: Ankylosing Spondylitis
Ankylosing Spondylitis
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis
- Trial name
- ASLeap (NCT03350815)
- Testing
- 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
- Where
- 65 sites in United States
- Volunteers
- 322 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Inflammatory Arthritis
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor…
- Conditions
- Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis
- Trial name
- NCT02538341
- Testing
- Herpes Zoster (HZ) Vaccine
- Where
- 34 sites in United States
- Volunteers
- 617 people
- Sponsor
- University of Alabama at Birmingham
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Ankylosing Spondylitis
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry
- Trial name
- NCT04507763
- Testing
- Etanercept
- Where
- Iraq
- Volunteers
- 763 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be…
- Trial name
- ASTRUM (NCT02763046)
- Testing
- Secukinumab (AIN457) 150 mg s.c.
- Where
- 39 sites in Germany
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
- Trial name
- NCT03502616
- Testing
- Tofacitinib
- Where
- 99 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Pfizer
Spondyloarthritis
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease…
- Trial name
- SKIPPAIN (NCT03136861)
- Testing
- AIN457
- Where
- 66 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
This study is designed as an extension study to the proof-of-concept trial CAIN457A2209 in patients with moderate to severe ankylosing spondylitis and aims to provide continuous treatment with AIN457 for patients in the core…
- Trial name
- NCT01109940
- Testing
- AIN457A
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese…
- Trial name
- NCT00762463
- Testing
- Celecoxib, Diclofenac SR
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ankylosing Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety…
- Trial name
- NCT02896127
- Testing
- Secukinumab
- Where
- 44 sites in China, Czechia and 2 more
- Volunteers
- 458 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthrithis, Ankylosing Spondylitis
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B).
- Trial name
- C-OPTIMISE (NCT02505542)
- Testing
- Certolizumab Pegol
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 736 people
- Sponsor
- UCB BIOSCIENCES GmbH
Rheumatoid Arthritis, Ankylosing Spondylitis
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128.
- Trial name
- NCT02328027
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Advanced Accelerator Applications
Ankylosing Spondylitis, Axial Spondyloarthritis
Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis
This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain…
- Trial name
- NCT03473665
- Testing
- Indomethacin, Diclofenac, Meloxicam
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Columbia University
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
- Trial name
- COAST-W (NCT02696798)
- Testing
- Ixekizumab
- Where
- 99 sites in United States, Argentina and 15 more
- Volunteers
- 316 people
- Sponsor
- Eli Lilly and Company
Spondylitis, Ankylosing
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
- Trial name
- RE-EMBARK (NCT02509026)
- Testing
- Etanercept
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 210 people
- Sponsor
- Pfizer
Ankylosing Spondyloarthritis
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines.
- Trial name
- POSTURE (NCT01583374)
- Testing
- Apremilast tablet 20 mg, Apremilast tablet 30 mg BID
- Where
- 103 sites in United States, Australia and 16 more
- Volunteers
- 490 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Ankylosing Spondylitis
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01060098
- Testing
- anti-TNF therapy (etanercept or adalimumab)
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Imperial College London
Rheumatoid Diseases, Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naïve to biologics or are switching from stable Remicade to…
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- PERSIST (NCT02605642)
- Testing
- CT-P13
- Where
- 38 sites in Bulgaria, Canada and 5 more
- Volunteers
- 351 people
- Sponsor
- Pfizer
Spondyloarthritis
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
This single center, open-label, proof of concept (PoC) Phase II study aimed to assess the investigational imaging agent 99mTc-rhAnnexin V-128 in detecting spondyloarthritis (SpA) lesions.
- Trial name
- Annexin 03 (NCT03232580)
- Testing
- rhAnnexin V-128
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Advanced Accelerator Applications